血液透析联合血液灌流治疗恶性高血压的临床效果分析

Analysis of the Clinical Effect of Hemodialysis Combined with Hemoperfusion in the Treatment of Malignant Hypertension

摘要: 本研究以慢性肾功能衰竭尿毒症期依靠血液透析维持生命的患者中伴恶性高血压为研究对象，观察两种不同治疗方式：1) 单纯血液透析 + 口服降压药物；2) 血液透析联合血液灌流 + 口服降压药物；对患者的血压控制情况进行评估，比较二者的临床疗效。进一步探讨血液透析联合血液灌流对慢性肾功能衰竭尿毒症期血液透析患者出现的恶性高血压的临床效果。纳入我院血液透析中心80例慢性肾功能衰竭尿毒症期血液透析患者同时伴有恶性高血压，使用随机数字表法对患者进行随机分组，利用统计软件SPSS23.0随机生成数字表，并根据数字形成与之对应的组别，按照各患者就诊顺序，对应其随机数字所属组别，确认其治疗方式，组别1为实验组，组别2为对照组，最后以1:1比例分配患者至实验组和对照组各40例。疗程设置：实验组为常规血液透析患者每两周增加1次血液灌流，4周为一个疗程，连续治疗3个疗程，治疗完成后8周随访。对照组为常规血液透析患者。观察血液透析联合血液灌流对慢性肾功能衰竭尿毒症期血液透析患者血压控制情况以及症状的改善情况，从而对其疗效进行评估。

Abstract: This study focused on patients with malignant hypertension in the uremic stage of chronic renal failure who relied on hemodialysis to maintain life, and observed two different treatment methods: 1) Simple hemodialysis + oral antihypertensive drugs; 2) Hemodialysis combined with hemoperfusion and oral antihypertensive drugs; The blood pressure control of the patients was evaluated and the clinical efficacy of the two was compared. To further explore the clinical effect of hemodialysis combined with hemoperfusion on malignant hypertension in patients with the uremic stage of chronic renal failure undergoing hemodialysis. A total of 80 patients with chronic renal failure in the uremic stage undergoing hemodialysis and accompanied by malignant hypertension were included in the hemodialysis center of our hospital. The patients were randomly grouped using the random number table method. The statistical software SPSS23.0 was used to randomly generate the number table, and the corresponding groups were formed based on the numbers. According to the order of each patient’s visit, the groups to which the random numbers belonged were determined. Confirm the treatment methods. Group 1 was the experimental group and Group 2 was the control group. Finally, 40 patients were assigned to each group in a 1:1 ratio. Treatment course setting: In the experimental group, conventional hemodialysis patients were given an additional hemoperfusion every two weeks. A course of treatment lasted for 4 weeks, and three consecutive courses were treated. A follow-up was conducted 8 weeks after the completion of the treatment. The control group consisted of patients undergoing conventional hemodialysis. To observe the blood pressure control and symptom improvement of hemodialysis combined with hemoperfusion in patients with chronic renal failure during the uremic stage undergoing hemodialysis, and thereby evaluate its therapeutic effect.